Roundtable Roundup: Choosing a Bispecific Antibody for R/R Multiple Myeloma

CASE SUMMARY

• A 72-year-old man was diagnosed 6 years ago with multiple myeloma, with 60% plasma cells and translocation 14;20.
• Medical history: respiratory infections (2 episodes of pneumonia and multiple episodes of bronchitis over prior 10 years)
• He received 5 prior lines of therapy, most recently chimeric antigen receptor T-cell infusion
• He now presents with progressive disease (elevated free light chain, creatinine level of 2.3 mg/dL)
• ECOG performance status: 2

CASE UPDATE

Talquetamab is initiated via step-up dosing (SUD) up to 800 μg/kg every 2 weeks (Q2W).